Suppr超能文献

平行合成策略在发现作为高效且选择性的 NaV1.7 抑制剂的联芳基酰基磺酰胺中的应用。

Application of a Parallel Synthetic Strategy in the Discovery of Biaryl Acyl Sulfonamides as Efficient and Selective NaV1.7 Inhibitors.

作者信息

DiMauro Erin F, Altmann Stephen, Berry Loren M, Bregman Howard, Chakka Nagasree, Chu-Moyer Margaret, Bojic Elma Feric, Foti Robert S, Fremeau Robert, Gao Hua, Gunaydin Hakan, Guzman-Perez Angel, Hall Brian E, Huang Hongbing, Jarosh Michael, Kornecook Thomas, Lee Josie, Ligutti Joseph, Liu Dong, Moyer Bryan D, Ortuno Daniel, Rose Paul E, Schenkel Laurie B, Taborn Kristin, Wang Jean, Wang Yan, Yu Violeta, Weiss Matthew M

机构信息

Department of Neuroscience, Amgen Inc. , One Amgen Center Drive, Thousand Oaks, California 91320, United States.

出版信息

J Med Chem. 2016 Sep 8;59(17):7818-39. doi: 10.1021/acs.jmedchem.6b00425. Epub 2016 Aug 29.

Abstract

The majority of potent and selective hNaV1.7 inhibitors possess common pharmacophoric features that include a heteroaryl sulfonamide headgroup and a lipophilic aromatic tail group. Recently, reports of similar aromatic tail groups in combination with an acyl sulfonamide headgroup have emerged, with the acyl sulfonamide bestowing levels of selectivity over hNaV1.5 comparable to the heteroaryl sulfonamide. Beginning with commercially available carboxylic acids that met selected pharmacophoric requirements in the lipophilic tail, a parallel synthetic approach was applied to rapidly generate the derived acyl sulfonamides. A biaryl acyl sulfonamide hit from this library was elaborated, optimizing for potency and selectivity with attention to physicochemical properties. The resulting novel leads are potent, ligand and lipophilic efficient, and selective over hNaV1.5. Representative lead 36 demonstrates selectivity over other human NaV isoforms and good pharmacokinetics in rodents. The biaryl acyl sulfonamides reported herein may also offer ADME advantages over known heteroaryl sulfonamide inhibitors.

摘要

大多数强效且具有选择性的hNaV1.7抑制剂具有共同的药效基团特征,包括一个杂芳基磺酰胺头部基团和一个亲脂性芳族尾部基团。最近,出现了类似芳族尾部基团与酰基磺酰胺头部基团结合的报道,其中酰基磺酰胺赋予的对hNaV1.5的选择性水平与杂芳基磺酰胺相当。从满足亲脂性尾部选定药效基团要求的市售羧酸开始,采用平行合成方法快速生成衍生的酰基磺酰胺。对该文库中得到的一个联芳基酰基磺酰胺命中物进行了优化,在关注物理化学性质的同时优化其效力和选择性。所得的新型先导化合物效力强、配体及亲脂性高效,且对hNaV1.5具有选择性。代表性先导化合物36对其他人类NaV亚型具有选择性,并且在啮齿动物中具有良好的药代动力学性质。本文报道的联芳基酰基磺酰胺与已知的杂芳基磺酰胺抑制剂相比,可能还具有药物吸收、分布、代谢和排泄方面的优势。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验